Global Irritable Bowel Syndrome Treatment Market - 2022-2029

Global Irritable Bowel Syndrome Treatment Market - 2022-2029

Market Overview

Irritable Bowel Syndrome Treatment Market size was valued US$ 1.806 million in 2021 and is estimated to reach US$ 3,835 million by 2029, growing at a CAGR of 7.9% during the forecast period (2022-2029).

Irritable Bowel Syndrome is the most common functional gastrointestinal (GI) disorder. That affects the large intestine. It is characterized by cramping, abdominal pain, bloating, gas, diarrhea, or constipation. The muscle contractions, abnormalities in the nerves in your digestive system, inflammation in the intestines, severe infection, and bacteria changes in the gut lead to irritable bowel syndrome development.

Market Dynamics

The global irritable bowel syndrome treatment market is growing due to several factors such as rising demand for irritable bowel syndrome treatments due to increasing prevalence of bowel syndrome, various new drugs and products launches and novel technological advancements.

Rising incidence of irritable bowel syndrome and various new technological advancements are expected to drive market growth.

The market is driven by the rising demand for irritable bowel syndrome therapies. The increasing prevalence of irritable bowel syndrome and the increasing stress level and adoption of irritable bowel syndrome. In Apr 2022 a report titled “Diarrhea predominant-irritable bowel syndrome (ibs-d): effects of different nutritional patterns on intestinal dysbiosis and symptoms” stated that IBS affects approx. 5% to 15% of the population and dominates women aged less than 50 years.

There is an increase in the number of novel drugs being approved to treat irritable bowel syndrome. For instance, in September 2019, Knight Therapeutics Inc. had received approval from the U.S. Food and Drug Administration (FDA) for IBSRELA (tenapanor) for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. BSRELA is a minimally-absorbed small molecule, a locally acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3), which effectively increases bowel movements and decreases abdominal pain in IBS-C patients.

In October 2019, Cipher Pharmaceuticals Inc. had received the Health Canada approval for TRULANCE (plecanatide) for adults with irritable bowel syndrome with constipation (IBS-C).

The market is witnessing technological advancement with the digital platforms for developing irritable bowel syndrome therapies to assess patients’ causes and symptoms better and treat them with appropriate medication. For instance, The IBS (Irritable Bowel Syndrome) Program by Buscomint and Cara Care is the first program to offer this type of approach to coping with this complex condition. The program features a new version of the Cara Care app that tracks symptoms and triggers and offers support to consumers from specialized dietitians.

Bold Health had launched a Zemedy, an app targeted at treating irritable bowel syndrome symptoms through a combination of CBT, hypnotherapy exercises, and stress management techniques.

Several organizations provide funding & grants for the research & development activities for irritable bowel syndrome products. For instance, in May 2019, metaMe Health had received a grant from the National Institutes of Health (NIH) for more than USD 240,000 to perform real-world testing on metaMe Health’s metaMe Connect digital therapeutics platform. Regular for Irritable Bowel Syndrome (IBS) would be the first digital therapeutic to be released on the platform.

Unavailability of a particular treatment for all the symptoms of disorder are expected to hamper the market growth.

The market is hindered by the unavailable particular treatment to treat all the symptoms of irritable bowel syndrome and high cost of the medicine due to competition between the key market players.

Global Irritable Bowel Syndrome Treatment Market - Industry Analysis

The global irritable bowel syndrome treatment market provides in-depth analysis of the market based on various industry factors such as Porter’s Five Forces, Regulatory Analysis, Supply Chain Analysis, Pricing Analysis.

Segment Analysis/B>

Disease type segment is expected to hold the largest market share in global irritable bowel syndrome treatment market

The irritable bowel syndrome treatment market is segmented based on disease type as IBS with Diarrhea (IBS-D), IBS with Constipation (IBS-C), and Mixed-Presentation IBS (IBS-M). The IBS with Constipation (IBS-C) segment is expected to have the largest market share as it is the most prevalent form of irritable bowel syndrome. Approximately 50% of people with irritable bowel syndrome are suffering from IBS with Constipation (IBS-C). It causes a sensation of an incomplete bowel movement, discomfort, or bloating, along with constipation. The major market players such as Allergan, Ironwood, Astellas, Knight Therapeutics, and AstraZeneca are developing IBS therapies with Constipation (IBS-C). The rise in the number of novel drug approvals and launches for IBS treatment with Constipation (IBS-C) shall stimulate market growth. For instance, in April 2020, Knight Therapeutics Inc. received approval from Health Canada for the IBSRELA (tenapanor) to treat irritable bowel syndrome with constipation (IBS-C) adults. In August 2019, Alfasigma USA, Inc. had launched ZELNORM (tegaserod), a prescription pharmaceutical treatment for irritable bowel syndrome with constipation (IBS-C) in adult women less than 65 years of age. Moreover, the expected approval of the novel therapies shall boost the market growth over the forecasted period.

The IBS with Diarrhea (IBS-D) segment is expected to have positive market growth owing to the increase in the prevalence of cases of IBS with Diarrhea. Approximately 30%, i.e., one-third of the people with irritable bowel syndrome, suffer from IBS with Diarrhea (IBS-D). Abnormal movement of colon and small intestines, full bowels, gastroenteritis, and other factors increase the risk of developing IBS with Diarrhea (IBS-D). The rising uptake of the drugs such as Xifaxan and Viberzi for IBS treatment with Diarrhea (IBS-D).

Further, the market is also classified based on Rifaximin, Eluxadoline, Lubiprostone, Linaclotide, etc. The Linaclotide segment accounts for the highest market share. The Linaclotide is marketed under the brand name Linzess in the United States by Ironwood and Allergan. It is marketed under the brand name Constella by Allergan in Europe. It is marketed under the brand name Linzess by Astellas in Japan and AstraZeneca in China, Hong Kong, and Macau, and Allergan in all other territories worldwide. The clinical trials have demonstrated that Linaclotide's administration reduced visceral hypersensitivity and improved constipation symptoms by increasing intestinal secretion and accelerating transit. The rising approval of the products with a new dose shall stimulate market growth.

Geographical Analysis

North America region holds the largest market share in the global irritable bowel syndrome treatment market

The irritable bowel syndrome treatment market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, North America dominated the irritable bowel syndrome treatment market due to the high prevalence of irritable bowel syndrome treatment. It is the most common disorder diagnosed by gastroenterologists and accounts for 12% of primary care providers' total visits. Approximately 30 million people are suffering from irritable bowel syndrome in the United States. According to the International Foundation for Gastrointestinal Disorders, approximately 2.4 and 3.5 million people visit physicians for irritable bowel syndrome treatment every year in the United States. The availability of novel products along with technological advancement shall fuel the market growth. There is a presence of a large number of companies developing irritable bowel syndrome products. Moreover, the companies raise awareness regarding the symptoms, etiology, diagnosis, and treatment of irritable bowel syndrome. For instance, in April 2019, Salix Pharmaceuticals, Ltd. had launched national initiatives in honor of irritable bowel syndrome awareness month to broaden understanding of advances in research and improve the recognition of symptoms for patients who live with chronic disease.

The Asia-Pacific region is expected to have positive market growth owing to the increasing approval of novel therapies for irritable bowel syndrome. Several factors, such as lifestyle factors including smoking, alcohol consumption, and physical activity, are playing a major role in increasing the prevalence of irritable bowel syndrome.

Competitive Landscape

The irritable bowel syndrome treatment market is highly competitive with the presence of several international and local markets. Technological advancement, revenue generation, and opportunities intensify the market competition. Abbott Laboratories, Allergan plc, Ardelyx Inc., Astellas Pharma Inc., AstraZeneca plc, GlaxoSmithKline Plc, Novartis AG, and Takeda Pharmaceutical Company Limited are the leading market players with significant market share.

The market players are using new product launches, novel product approvals, market expansion, and technological advancement strategies for holding their market position. For instance, in January 2020, OrphoMed, Inc. had initiated a Phase II response-adaptive clinical study (PREVAIL trial) of ORP-101 to treat irritable bowel syndrome with diarrhea (IBS-D). ORP-101 is a new chemical entity designed to create a large stable molecule and confer partial μ agonist and full κ-antagonist receptor pharmacology.

The companies are entering into collaborations, mergers, strategic partnerships, and acquisitions to increase the demand for irritable bowel syndrome and their expansion across the globe. For instance, in April 2020, HiDoc Technologies GmbH, dba Cara Care had entered into the collaboration with the Consumer Healthcare Business Unit of Sanofi for the holistic approach to digestive health that bundles Sanofi’s Buscomint be Reizdarm pharmaceutical drug with Cara Care’s digital companion app for digestive conditions.

In June 2019, Alfasigma USA, Inc. had acquired the brand ZELNORM, a prescription pharmaceutical treatment for irritable bowel syndrome with constipation (IBS-C), from Sloan Pharma S.à r.l., a subsidiary of US WorldMeds Holdings, LLC.

The companies are raising the funding and investment to increase their market penetration. In August 2019, metaMe Health had raised USD 3.8 million in funding for initiating a controlled trial to study the efficacy and safety of Regular in IBS patients and fund its pre-commercialization efforts.

Key Companies to Watch

Abbott Laboratories:

Overview: Abbott is American multinational company that develops medical devices and healthcare products. It was founded in 1888 and is headquartered in Illinois, United States. Their products and services include medical devices, diagnostics, nutritional products and branded generic medicines.

Product Portfolio:

Colospa Retard: It is a medicine that is used for relieve and treatment of symptoms of irritable bowel syndrome. It relaxes intestine muscles and relieves stomach pain, cramps in abdomen, changes in bowel system and bloating.

Key Developments: In Nov 2021 Abbott launched Similac 360 which consist of 5 HMO prebiotics and developed to strengthen the digestive health and immune system.

The global irritable bowel syndrome treatment market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.